Gujarat Kidney and Super Speciality Ltd
Gujarat Kidney and Super Speciality Ltd (GKSL) last traded at ₹152, a market capitalisation of ₹1,201 crore, on a P/E of 75.8. Over the past 52 weeks the stock has ranged between ₹98.2 and ₹162. Gujarat Kidney and Super Speciality Ltd last reported results for the quarter ended Jun 2026, with sales of ₹34.29 crore and net profit of ₹5.32 crore. Gujarat Kidney and Super Speciality Ltd’s annual general meeting is scheduled for 28 Sept 2026. Figures are as of 25 Aug 2026 and are not real time.
Gujarat Kidney and Super Speciality Ltd share price and key metrics
Metrics as of 25 Aug 2026. Not real time.
Gujarat Kidney and Super Speciality Ltd quarterly results
In the quarter ended Jun 2026, sales were ₹34.29 cr, up 124.7% from ₹15.26 cr a year earlier. Net profit was ₹5.32 cr, down 1.5% year on year.
| ₹ crore | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 9.41 | 11.79 | 9.78 | 15.26 | 12.93 | 23.25 | 30.58 | 34.29 |
| Expenses | 4.55 | 7.19 | 7.17 | 6.64 | 7.81 | 16.35 | 24.28 | 25.92 |
| Operating profit | 4.86 | 4.6 | 2.61 | 8.62 | 5.12 | 6.9 | 6.3 | 8.37 |
| OPM % | 51.65% | 39.02% | 26.69% | 56.49% | 39.60% | 29.68% | 20.60% | 24.41% |
| Other income | 0.04 | 0.05 | 0.05 | 0.01 | 0.09 | 0.06 | 0.71 | 0.69 |
| Interest | 0.16 | 0.17 | 0.16 | 0.18 | 0.28 | 0.6 | 0.82 | 0.66 |
| Depreciation | 0.74 | 0.88 | 0.9 | 0.96 | 0.9 | 1.33 | 1.51 | 1.44 |
| Profit before tax | 4 | 3.6 | 1.6 | 7.49 | 4.03 | 5.03 | 4.68 | 6.96 |
| Tax % | 26.25% | 29.72% | 16.88% | 27.77% | 28.54% | 26.44% | -2.99% | 23.56% |
| Net profit | 2.96 | 2.53 | 1.34 | 5.4 | 2.88 | 3.7 | 4.82 | 5.32 |
| EPS (₹) | 18.39 | 15.53 | 0.23 | 0.85 | 0.47 | 0.37 | 0.64 | 0.66 |
Consolidated figures as reported by the company. Percentages are as published; totals may not sum exactly.
Gujarat Kidney and Super Speciality Ltd annual results
| ₹ crore | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|
| Sales | 0 | 5 | 40 | 82 | 101 |
| Operating profit | -0 | 2 | 17 | 27 | 27 |
| OPM % | — | 41% | 41% | 33% | 26% |
| Net profit | -0 | 2 | 10 | 17 | 17 |
| EPS (₹) | -0.50 | 85.50 | 1.66 | 1.97 | 2.14 |
TTM is the trailing twelve months to the most recent quarter.
Gujarat Kidney and Super Speciality Ltd growth and returns
- 10 Years
- %
- 5 Years
- %
- 3 Years
- %
- TTM
- 119%
- 10 Years
- %
- 5 Years
- %
- 3 Years
- 1058%
- TTM
- 37%
- 10 Years
- %
- 5 Years
- %
- 3 Years
- %
- 1 Year
- %
- 10 Years
- %
- 5 Years
- %
- 3 Years
- 16%
- Last Year
- 11%
Gujarat Kidney and Super Speciality Ltd shareholding pattern
Promoters held 71.45% at Jun 2026, broadly unchanged since Dec 2025. FIIs 4.89% and DIIs 0.56%.
| % held | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|
| Promoters | 71.45% | 71.45% | 71.45% |
| FIIs | 10.47% | 4.89% | 4.89% |
| DIIs | 1.67% | 0.56% | 0.56% |
| Public | 16.40% | 23.10% | 23.10% |
| No. of shareholders | 27,783 | 18,301 | 18,301 |
As disclosed by the company to the exchanges. The last row is a count of shareholders, not a percentage.
When is Gujarat Kidney and Super Speciality Ltd’s AGM?
Gujarat Kidney and Super Speciality Ltd’s annual general meeting is scheduled for 28 Sept 2026.
- AGMConvening of the 7th Annual General Meeting
See the full results calendar for every Indian company reporting in the next 30 days.
Gujarat Kidney and Super Speciality Ltd corporate filings
- Outcome of Board meeting held on 24-08-2026 for appointment of Additional Director, subject to approval of shareholders at ensuing Annual General Meeting and taking note of approval of ....Otherslow impact
Cruxal's analysis: Gujarat Kidney and Super Speciality Limited has appointed Dr. Disha Bharpoda as an…
Read the full analysis - Postal ballot Result declared.AGM/EGMlow impact
Cruxal's analysis: Gujarat Kidney and Super Speciality Limited has received shareholder approval via postal…
Read the full analysis - Monitoring Agency Report June 2026Company Updatelow impact
Cruxal's analysis: The company has submitted its Monitoring Agency Report for the period ending June 2026 in…
Read the full analysis - Statement of Deviation & Variation as on June 30, 2026Company Updatelow impact
Cruxal's analysis: The company has submitted its Statement of Deviation or Variation regarding the…
Read the full analysis - Change in Category of Mr Paresh Dhoti from Additional Director - Non Executive- Non Independent to Additional Director- Non Executive-Independent (appointment shall be subject to approval ....Company Updatelow impact
Cruxal's analysis: Gujarat Kidney And Superspeciality Limited has announced the appointment of Mr. Paresh…
Read the full analysis - Outcome of Board meeting for consideration of Unaudited financial results and other matters.Board Meetingmedium impact
Cruxal's analysis: Gujarat Kidney and Superspeciality Limited reported standalone revenue of 9.24 crore for…
Read the full analysis - Gujarat Kidney And Super Speciality Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/08/2026 ,inter alia, to consider and approve Unaudited ....Board Meetinglow impact
Cruxal's analysis: Gujarat Kidney And Superspeciality Limited has formally notified the stock exchanges that…
Read the full analysis
This page shows filings on a one-hour delay. Sign in to see them as they land, with Cruxal's analysis of what each one means.
Track Gujarat Kidney and Super Speciality Ltd
Cruxal reads every Gujarat Kidney and Super Speciality Ltd filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.
Cruxal publishes market data and coverage for information only. Nothing here is investment advice.